InvestorsHub Logo
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
daytona52paul Free
05/15/15 1:54 PM
profile icon
daytona52paul Free
05/15/15 1:33 PM
profile icon
daytona52paul Free
05/15/15 1:26 PM
profile icon
daytona52paul Free
05/15/15 1:14 PM
profile icon
daytona52paul Free
05/15/15 1:09 PM
profile icon
daytona52paul Free
05/15/15 1:07 PM
profile icon
daytona52paul Free
05/15/15 1:00 PM
profile icon
daytona52paul Free
05/15/15 12:54 PM
profile icon
daytona52paul Free
05/15/15 12:43 PM
profile icon
daytona52paul Free
05/15/15 12:40 PM
profile icon
daytona52paul Free
05/15/15 12:29 PM
profile icon
daytona52paul Free
05/15/15 12:27 PM
profile icon
stocktrademan Free
05/15/15 12:20 PM
profile icon
daytona52paul Free
05/15/15 12:19 PM
profile icon
crudeoil24 PremiumMember
05/15/15 9:50 AM
profile icon
Tdash Free
05/14/15 3:31 PM
profile icon
123414 Free
05/12/15 9:56 AM
profile icon
THREE-DAY-TRADER Free
05/11/15 11:26 AM
profile icon
CashFreeze Free
05/11/15 10:25 AM
profile icon
THREE-DAY-TRADER Free
05/11/15 9:56 AM
profile icon
THREE-DAY-TRADER Free
05/10/15 10:32 PM
profile icon
THREE-DAY-TRADER Free
05/10/15 1:44 PM
profile icon
THREE-DAY-TRADER Free
05/08/15 7:45 PM
profile icon
THREE-DAY-TRADER Free
05/08/15 5:22 PM
profile icon
THREE-DAY-TRADER Free
05/06/15 3:07 PM
profile icon
THREE-DAY-TRADER Free
05/05/15 9:34 PM
profile icon
dave86 Free
05/05/15 4:27 PM
profile icon
THREE-DAY-TRADER Free
05/05/15 4:25 PM
profile icon
dave86 Free
04/30/15 4:48 PM
profile icon
croptop Free
04/30/15 2:53 PM
profile icon
dave86 Free
04/30/15 2:51 PM
profile icon
croptop Free
04/28/15 10:59 AM
profile icon
ListenToMe Free
01/04/15 4:36 PM
profile icon
ListenToMe Free
01/02/15 3:05 PM
profile icon
LARRYMONEY Terminated
12/29/14 10:16 AM
profile icon
ListenToMe Free
12/29/14 9:28 AM
profile icon
ListenToMe Free
12/28/14 9:39 AM
profile icon
jloerke Free
12/26/14 3:43 PM
profile icon
ListenToMe Free
12/26/14 1:21 PM
profile icon
ListenToMe Free
12/26/14 11:22 AM
profile icon
DITRLI Free
12/15/14 3:10 AM
profile icon
DITRLI Free
12/12/14 1:39 PM
profile icon
someconcerns Free
08/11/14 5:29 PM
profile icon
White Hat Bitsuk Free
06/06/14 9:47 AM
profile icon
rawiron1 Free
02/16/14 10:57 PM
profile icon
TaperT2 Free
02/16/14 8:34 PM
profile icon
green is good Free
01/19/14 4:41 PM

Cascadian Therapeutics (CASC) RSS Feed

Followers
61
Posters
168
Posts (Today)
0
Posts (Total)
792
Created
05/16/06
Type
Free
Moderators

company web-site - http://www.oncothyreon.com
recent event / CC - http://ir.oncothyreon.com/events.cfm -

Oncothyreon is a biotechnology company dedicated to the development of oncology products that can improve the lives and outcomes of cancer patients. We are currently developing multiple therapeutic candidates designed to target cancer in specific and effective ways. Our pipeline includes both synthetic vaccines and small molecules for a variety of cancer indications.  Oncothyreon is headquartered in Bellevue, Washington. The Company is traded on the NASDAQ National Market under the symbol ONTY and on the Toronto Stock Exchange under the symbol ONY.   We are The Cancer Vaccine People(TM).

Stimuvax

ONTY's drug Stimuvax, in partnership with Merck KGaa, is now in large Phase 3 Pivotal Trial program for NSCLC:

Phase III NSCLC (Lung) "START" Trial - http://www.clinicaltrials.gov/ct2/show/NCT00409188

Phase III NSCLC "INSPIRE" Trial (Asia) - http://www.clinicaltrials.gov/ct2/show/NCT01015443

Phase II NSCLC w/Avastin Trial - http://www.clinicaltrials.gov/ct2/show/NCT00828009

Phase I/II NSCLC Trial in Japan http://www.clinicaltrials.gov/ct2/show/NCT00960115

Phase IV Long-Term Safety Trial - http://www.clinicaltrials.gov/ct2/show/NCT01423760

Phase II HDPC Trial - http://bethesdatrials.cancer.gov/clinical-research/search_detail.aspx?ProtocolID=NCI-11-C-0247

 Pipe-Line - http://www.oncothyreon.com/pipeline/overview.html

Remaining Pipe-Line -

ONT-10 - http://www.oncothyreon.com/pipeline/vaccines/ONT-10/overview.html

PX-866 - http://www.oncothyreon.com/pipeline/small/PX-866/overview.html

          Start of Trial with Taxotere - http://ir.oncothyreon.com/releasedetail.cfm?ReleaseID=526661

          Start of Trial with Erbitux - http://ir.oncothyreon.com/releasedetail.cfm?ReleaseID=537953

PRESS RELEASES

Oncothyreon Initiates Phase 2 Trial of its PI-3 Kinase Inhibitor PX-866 in Patients with Glioblastoma - http://ir.oncothyreon.com/releasedetail.cfm?ReleaseID=561867

Oncothyreon Presents Preclinical Data for ONT-10 and PX-866 at American Association for Cancer Research - http://ir.oncothyreon.com/releasedetail.cfm?ReleaseID=561521

Oncothyreon Announces Publication of Safety & Survival Data From Stimuvax Phase 1/2 NSCLC Trial - http://ir.oncothyreon.com/releasedetail.cfm?ReleaseID=515788

Oncothyreon Initiates Phase 1/2 Trial of its PI-3 Kinase Inhibitor PX-866 in Combination with Cetuximab - http://ir.oncothyreon.com/releasedetail.cfm?ReleaseID=537953

Oncothyreon announces that Merck Serono is resuming the Stimuvax clinical program in lung cancer - http://ir.oncothyreon.com/releasedetail.cfm?ReleaseID=480296

Oncothyreon announces temporary suspension of Stimuvax clinical trials - http://ir.oncothyreon.com/releasedetail.cfm?ReleaseID=453976

Oncothyreon announces STRIDE Phase 3 BC trial - June 22, 2009 http://investorshub.advfn.com/boards/read_msg.aspx?message_id=38926533

Oncothyreon announces clinical data at ASCO - May 30, 2009 - http://investorshub.advfn.com/boards/read_msg.aspx?message_id=38259984

Oncothyreon announces development plans - Dec. 18, 2008 - http://biom.client.shareholder.com/releasedetail.cfm?ReleaseID=355043

Merck KGaA buys manufacturing rights for Stimuvax - Dec. 18, 2008 - http://biom.client.shareholder.com/releasedetail.cfm?ReleaseID=355037

ONTY/Merck KGaA amend agreements - Aug 8, 2007http://www.marketwatch.com/news/story/biomira-merck-kgaa-sign-amended/story.aspx?guid=%7B43FD62A1%2D....

MEDICAL PRESENTATIONS

ASCO 2007 Stimuvax Abstract - http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID=32165

"16 pts were evaluated for this interim safety analysis ..........As of September 2006, 10 pts were still on study treatment."

ASCO 2008 Stimuvax Abstract - http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=34755

"The 2-year survival rate of 64% ....compares favorably with previously reported survival for chemoradiation in stage III NSCLC."

ASCO 2009 Stimuvax Abstract - http://www.abstract.asco.org/AbstView_65_31704.html

"a remarkable # of pts received prolonged treatment...16 pts received L-BLP25 for 2.0-7.7 years, 10 pts were treated for >5 years."

COMPLETE MEDICAL PAPERS

  Paper summarizing all Stimuvax trials to date - http://investorshub.advfn.com/boards/read_msg.aspx?message_id=39761211

  Publication of Data From Phase 1/2 NSCLC Trial - http://ir.oncothyreon.com/releasedetail.cfm?ReleaseID=515788 

  A Peptide Vaccine Strategy in NSCLC - http://investorshub.advfn.com/boards/read_msg.aspx?message_id=39627241

 Phase IIb Trial in NSCLC Stage IIIB and IV - http://investorshub.advfn.com/boards/read_msg.aspx?message_id=39099793

"The greatest difference in survival was observed in stage IIIB LR patients (adjusted HR = 0.524; 95% CI, 0.261 to 1.052; P = .069)"

 - Fig 3. Overall survival by study arm - http://jco.ascopubs.org/cgi/content-nw/full/23/27/6674/F3

 - Fig 4. Survival analysis for stage IIIB with MFE or stage IV patients - http://jco.ascopubs.org/cgi/content-nw/full/23/27/6674/F4

 - Fig 5. Survival analysis for stage IIIB locoregional patients - http://jco.ascopubs.org/cgi/content-nw/full/23/27/6674/F5


 Detailed Description of START Trial - http://investorshub.advfn.com/boards/read_msg.aspx?message_id=39062424

First Interim Look - http://investorshub.advfn.com/boards/read_msg.aspx?message_id=58060227


 

Volume:
Day Range:
Last Trade Time:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
CASC Latest News
  • No Recent News Available for this company!
New Post